Cheng-ta J. Yang
Chiayi Branch 61363
Jiayi Shi, TNQ 61363, Taiwan
Jiayi Shi, TNQ 61363, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 267 publications
Modular serial-parallel network for hierarchical facial representations.
Journal: Psychological review
Published: August 31, 2026
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.
Journal: Targeted oncology
Published: April 29, 2026
Explicit feedback on target rewards modulates attentional bias in redundant-target detection.
Journal: Attention, perception & psychophysics
Published: April 21, 2026
Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.
Journal: Physical review letters
Published: March 24, 2026
Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.
Journal: Physical review letters
Published: March 24, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).
Journal: Future oncology (London, England)
Published: February 05, 2026
Processing efficiency predicts cognitive performance in aging.
Journal: Scientific reports
Published: January 26, 2026
Oxytocin mediates self-other and inevitability asymmetries in high-conflict moral judgment in schizophrenia.
Journal: Asian journal of psychiatry
Published: January 26, 2026
Longitudinal associations among childhood trauma, oxytocin, and metabolic risk in schizophrenia.
Journal: Psychiatry research
Published: December 31, 2025
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.
Journal: Targeted oncology
Published: December 05, 2025
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.
Journal: Therapeutic advances in medical oncology
Published: November 28, 2025
Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.
Journal: Cancer medicine
Published: October 11, 2025
Last Updated: 09/26/2026